Yiviva

02/05/2024

Yiviva is excited to partner with AstraZeneca to develop systems biology platforms and innovative medicines to help patients worldwide.

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology...

04/13/2022

This week at the 2022 American Association for Cancer Research (AACR) Annual Conference, Yiviva and Yale School of Medicine scientists presented promising preclinical data highlighting mechanism of action studies showing the potential of YIV-906 to modulate both adaptive immunity and innate immunity and facilitate immune checkpoint blockade therapy or CAR T-cell therapy for the treatment of

- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach to turn cold tumors hot - YIV-906 could increase...

03/25/2021

Yiviva announces the dosing of first patient in Phase 2b CALM clinical study of YIV-906 plus sorafenib combination therapy in the first-line treatment of hepatocellular carcinoma.

To learn more about this global clinical trial, led regionally by Memorial Sloan Kettering, National Cancer Center in Beijing, Queen Mary Hospital in Hong Kong and Taipei Medical University, please visit:

- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach -- Global study to evaluate efficacy, safety, and...

03/25/2021

To learn more about active clinical trials with YIV-906 (formerly known as PHY906), supported by the National Cancer Institute (NCI), please visit:

NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying chinese herbal formulation phy906.

03/25/2021

National Foundation for Cancer Research funding supports world-first Phase II multi-regional clinical trial for a botanical cancer drug candidate (YIV-906).

Yiviva launches liver cancer clinical trial to treat hepatitis B (+) hepatocellular carcinoma patients in the United States, Mainland China, Hong Kong and Taiwan, with sorafenib +/- immune enhancer YIV-906 in the front line.

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer. Being tested in the first line setting is a first-in-class botanical drug candidate, YIV-906, whose development has been supported....

03/25/2021

Yale University reports how advancing ancient medicines, using modern science, technology and manufacturing unlocks new possibilities for cancer treatment to treat unmet medical needs

After 20 years of research, Yale pharmacologist Yung-Chi Cheng and his partners are launching the first international clinical trial for a botanical drug.

03/25/2021

National Geographic features Yiviva co-founders (Yung-Chi Cheng, Shwu-Huey Liu and Peikwen Cheng) and YIV-906 (PHY906) in the issue “The Future of Medicine” and the story “How New Technologies and Ancient Remedies are Modernizing Medicine”.

To access the full article, please visit: https://yiviva.com/news/

https://www.nationalgeographic.com/magazine/article/ancient-chines-remedies-changing-modern-medicine

Long overlooked by Western science, traditional Chinese treatments are yielding cutting-edge cures.

03/25/2021

Immunomodulator YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint inhibitor (Anti-PD1) against liver cancer by changing the tumor micro-environment, demonstrating a vaccine-like effect.

To learn more about what renowned Yale researchers Yung-Chi Cheng (Henry Bronson Professor of Pharmacology) and Lieping Chen's (Co-Leader, Cancer Immunology, Yale Cancer Center) discovered, please visit:

Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA YIV-906 (PHY906) is inspired by a traditional 1800-year Chinese herbal formulation, “Huang Qin Tang”, which is commonly used for treating diarrhea. Following chemotherapy and radiation, preclinical and clinical results su...

03/25/2021

In liver cancer preclinical studies, YIV-906 enhances the immune response for sorafenib and potentiates anti-tumor activity against hepatocellular carcinoma.

To learn more about what researchers at Yale and City of Hope discovered about YIV-906 as an immune enhancer and immunomodulator, please visit:

03/25/2021

Liver cancer patients with Hepatitis B (+) had a higher median overall survival (>16.5 months) in a Phase I/II study of YIV-906 (PHY906) plus capecitabine in advanced hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles.

To learn about this clinical study at Stanford, Yale and City of Hope, please visit:

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combinat...

03/25/2021

Clinicians observe in a Phase II study that YIV-906 (PHY906) plus capecitabine provides a safe and feasible second line therapy after gemcitabine failure for patients with advanced pancreatic cancer.

To learn more about this clinical study at Tufts University, VA Connecticut Health Systems and Yale University, please visit:

Preclinical studies showed a Chinese botanical formula, PHY906, has synergistic anti-tumor activity with capecitabine. Our phase I study determined maximal tolerated dose of capecitabine 1500mg/m[2] BID day 1–7 and PHY906 800mg BID day 1–4 ...

03/25/2021

Re**al cancer patients treated with chemo-radiation concurrent with YIV-906 (formerly known as KD018) showed decreased GI toxicity without compromising tumor control – demonstrating better safety and patient outcomes in a Phase I/II study compared to historical controls

To learn more about this clinical study at Yale, please visit:

e15162 Background: Neo-adjuvant chemo-radiation (CRT) is commonly used for re**al cancer, though is associated with gastrointestinal (GI) toxicity. KD018 is a state-of-the-art adaptation of Huang-Qin-Tang, a traditional Chinese medicine used to treat GI ailments. KD018 is a standardized pharmaceutic...